Allergic Conjunctivitis
📧 Sign up to get email alerts when something new happens for Allergic Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2015-10-08FDA Approved: PATADAY ONCE DAILY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for Pataday Once Daily Relief to update the labeling for olopatadine hydrochloride, expanding its la…
-
CLINICAL_TRIALS trial_result · 2015-10-07Clinical Trial Update: The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel
This clinical trial update notes that the Ambrosia-related study in Israel addressing allergic rhinitis and asthma has completed.
-
FDA approval · 2015-09-30FDA Approved: LASTACAFT — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for LASTACAFT (alcaftadine) submitted by Allergan, Inc.
-
FDA approval · 2015-09-18FDA Approved: EYE ALLERGY RELIEF — Supplemental Application (DOLGENCORP, LLC)
FDA approved a supplemental application for Eye Allergy Relief containing pheniramine maleate and naphazoline hydrochloride, filed by Dolgen…
-
FDA label_change · 2015-09-16FDA Approved: ZADITOR — Supplemental Application (Alcon Laboratories, Inc.)
The FDA approved a supplemental application for Zaditor (ketotifen fumarate) submitted by Alcon Laboratories, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-08-18FDA Approved: EPINASTINE HYDROCHLORIDE — Supplemental Application (Somerset Therapeutics, LLC)
FDA approved a supplemental application for epinastine hydrochloride (generic product) by Somerset Therapeutics, LLC.
-
CLINICAL_TRIALS trial_result · 2015-08-06Clinical Trial Update: Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis [Phase 2]
Phase 2 safety and efficacy study of AL-53817 and AL-78843 ophthalmic solutions for allergic conjunctivitis has completed with results poste…
-
FDA approval · 2015-07-31FDA Approved: NAPHCON A — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for NAPHCON A (naphazoline hydrochloride and pheniramine maleate) by Alcon Laboratories, Inc.
-
FDA approval · 2015-06-30FDA Approved: PATADAY TWICE A DAY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for Pataday Twice a Day Relief (olopatadine hydrochloride) by Alcon Laboratories, Inc.
-
CLINICAL_TRIALS trial_result · 2015-06-26Clinical Trial Update: Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense [Phase 2]
Phase 2 trial comparing different up-dosing schedules of Osiris Phleum Pratense (timothy grass pollen extract) for allergic rhinitis with co…
-
CLINICAL_TRIALS trial_result · 2015-06-25Clinical Trial Update: Vitamin D and Grass Pollen Specific Immunotherapy [Phase 2]
Phase 2 trial evaluating vitamin D as an adjunct to grass pollen-specific immunotherapy for allergic rhinoconjunctivitis has completed.
-
FDA approval · 2015-05-12FDA Approved: EYE ALLERGY RELIEF — Supplemental Application (DOLGENCORP, LLC)
The FDA granted a supplemental approval for Eye Allergy Relief (pheniramine maleate and naphazoline hydrochloride) from DolGenCorp, LLC, und…
-
CLINICAL_TRIALS trial_result · 2015-05-12Clinical Trial Update: Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients [Phase 4]
Phase 4 clinical evaluation of 0.1% olopatadine hydrochloride ophthalmic solution in pediatric patients for allergic conjunctivitis has been…
-
FDA approval · 2015-04-13FDA Approved: CHILDRENS CETIRIZINE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Children's Cetirizine Hydrochloride (cetirizine hydrochloride) from Sun Pharmaceutical Indus…
-
CLINICAL_TRIALS trial_result · 2015-03-03Clinical Trial Update: Safety and Comfort of AL-4943A Ophthalmic Solution [Phase 1]
Phase 1 trial update assessing safety and comfort of AL-4943A ophthalmic solution for allergic conjunctivitis has completed.
-
CLINICAL_TRIALS withdrawal · 2015-02-20Clinical Trial Update: A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis [Phase 2]
A Phase 2 clinical trial evaluating a new treatment for allergic conjunctivitis has been withdrawn. The sponsor indicates the study will not…
-
CLINICAL_TRIALS trial_result · 2015-02-20Clinical Trial Update: Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers [Phase 3]
A Phase 3 safety study of an ophthalmic solution for allergic conjunctivitis completed in healthy volunteers.
-
FDA approval · 2015-02-11FDA Approved: EYE ITCH RELIEF — Supplemental Application (Target Corporation)
The FDA approved a supplemental application for Eye Itch Relief (ketotifen fumarate) by Target Corporation. The product is an ophthalmic tre…
-
CLINICAL_TRIALS trial_result · 2015-02-09Clinical Trial Update: Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan [Phase 4]
Phase 4 trial in Japan evaluating the effectiveness of olopatadine HCl ophthalmic solution for allergic conjunctivitis has completed and res…
-
FDA approval · 2015-01-30FDA Approved: PATADAY ONCE DAILY RELIEF — Original Application (Alcon Laboratories, Inc.)
FDA approved Pataday Once Daily Relief (olopatadine hydrochloride) from Alcon Laboratories in an Original Application for the treatment of a…
-
FDA approval · 2014-12-04FDA Approved: LASTACAFT — Supplemental Application (Allergan, Inc.)
FDA approves Allergan's supplemental application for LASTACAFT (alcaftadine), leading to changes in the product labeling.
-
CLINICAL_TRIALS trial_result · 2014-11-05Clinical Trial Update: Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis [Phase 3]
Phase 3 study of DE-114 ophthalmic solution for allergic conjunctivitis has completed and results have been posted.
-
FDA approval · 2014-10-29FDA Approved: DYMISTA — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DYMISTA (azelastine hydrochloride and fluticasone propionate) from Viatris Specialty LLC, under …
-
FDA approval · 2014-10-08FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Apotex Corp.)
FDA approved a generic olopatadine hydrochloride product (Apotex Corp.) under an Original Application.
-
CLINICAL_TRIALS trial_result · 2014-09-23Clinical Trial Update: A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis [Phase 3]
This document reports the completed Phase 3 long-term study of DE-114 Ophthalmic Solution for allergic conjunctivitis, with results posted i…